In this respect, the results of previous laboratory studies have indicated that metformin exerts a concentration-dependent cytotoxic effect on pancreatic cancer cells, and promotes significant activation of the AMPK pathway and downregulation of mTOR signaling, an important downstream effector of the PI3K/Akt pathway [3,33,34,35,36]. The gene discussed is MTOR; the disease is familial pancreatic carcinoma.